Pfizer & BioNTech's COVID-19 Vaccine Sales Top $3.3B Despite Legal Battle
Pharmaceutical giants Pfizer and BioNTech raked in over $3.3 billion from their COVID-19 vaccine Comirnaty in 2023. Meanwhile, they've been locked in a legal battle with Moderna over patent infringements, with both companies' vaccine sales declining significantly in 2024 as the pandemic subsided.
The legal saga began in September 2022 when Pfizer and BioNTech sued Moderna in London, challenging two of its patents. They argued that Moderna's mRNA technology developments were obvious, and thus the patents should be invalid. Moderna swiftly countersued, alleging patent infringement by Pfizer and BioNTech. This lawsuit is part of a broader global dispute between the three companies over their competing COVID-19 vaccines.
The latest development saw Pfizer and BioNTech appealing a UK court ruling that their COVID-19 vaccine infringed a Moderna patent. The appeal seeks to overturn this ruling. As of July 2023, multiple lawsuits concerning the validity of mRNA-related patents were ongoing at the Unified Patent Court in The Hague, involving the same patents contested against all parties. Moderna is defending itself with a different legal team, while BioNTech and Pfizer rely on their own counsel. These cases are part of broader litigation initiated by GSK and Bird & Bird against the three companies relating to three mRNA patents.
Moderna also generated over $3.2 billion in revenue from its COVID-19 vaccine Spikevax in 2023. Despite the decline in sales, both companies continue to invest in their vaccines and explore new applications, even as the legal battle rages on.
Read also:
- U.S. CBP's Operation Plaza Spike Boosts Fentanyl Seizures Along Arizona-Mexico Border
- Tesla's EV Market Share Plummets in Europe, US Competition Intensifies
- Catastrophe at a U.S. Steel facility in Pennsylvania results in the loss of two lives. crucial details unveiled
- Auto Industry Updates: Geotab, C2A, Deloitte, NOVOSENSE, Soracom, and Panasonic in Focus
